CD8A and Miyoshi myopathy: Aside from these outlooks, we expect that introduction of the VISTA-associated T-cell exclusion score and enhanced understanding of CD8+ T-cell immunity in MM will facilitate future development of the blockade of VISTA, being in line with reports that point to VISTA as an actionable target in other cancers such as mesothelioma [1,8].